Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + Letrozole in first-line HR+/HER2- advanced breast cancer
NCT07285382Phase 2Recruiting
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib in breast cancer. Started Jun 2025; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07285382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285382.